Clinical trial
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2…
NCT00246298 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Terminated
Key facts
| NCT number | NCT00246298 |
|---|---|
| Title | A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients |
| Official title | A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT (Epoetin Alfa) Dosing at Q2W vs. PROCRIT Dosing at QW in Anemic HIV-infected Subjects |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, HIV |
| Intervention type | Drug |
| Interventions | epoetin alfa |
| Enrollment | 31 |
| Start date | Oct 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Oct 31, 2005 |
| Last update posted | Jun 10, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: